Leila E Mansoor
Overview
Explore the profile of Leila E Mansoor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
2268
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gengiah T, Heck C, Lewis L, Mansoor L, Harkoo I, Myeni N, et al.
J Int AIDS Soc
. 2025 Feb;
28(2):e26426.
PMID: 39981604
Introduction: Long-acting HIV pre-exposure prophylaxis promises to improve uptake, adherence and persistence challenges experienced with daily oral tablets. We assessed the acceptability of an annual tenofovir alafenamide (TAF) implant in...
2.
Zondo N, Sobia P, Sivro A, Ngcapu S, Mahomed S, Mansoor L, et al.
AIDS Res Ther
. 2025 Feb;
22(1):18.
PMID: 39955595
Globally HIV remains a major public health problem. In sub-Saharan Africa most new HIV infections occur in adolescent girls and young women. Previously tested antiretroviral drugs as different pre-exposure prophylaxis...
3.
Beesham I, Beksinska M, Milford C, Mansoor L
Front Glob Womens Health
. 2025 Jan;
5():1505643.
PMID: 39839315
Background: Disclosure of oral pre-exposure prophylaxis (PrEP) use for HIV prevention may improve adherence to PrEP; however, disclosure can be challenging and may result in stigma. Here, we describe disclosure...
4.
Husnik M, Heffron R, Hughes J, Richardson B, van der Straten A, Palanee-Phillips T, et al.
AIDS Behav
. 2024 Aug;
28(11):3873-3882.
PMID: 39158801
Product adherence is critical to obtaining objective estimates of efficacy of pre-exposure prophylactic interventions against HIV-1 infection. With imperfect adherence, intention-to-treat analyses assess the collective effects of complete, sub-optimal and...
5.
Bekker L, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W, et al.
N Engl J Med
. 2024 Jul;
391(13):1179-1192.
PMID: 39046157
Background: There are gaps in uptake of, adherence to, and persistence in the use of preexposure prophylaxis for human immunodeficiency virus (HIV) prevention among cisgender women. Methods: We conducted a...
6.
Naidoo K, Montgomery E, Katz A, Garcia M, Naidoo S, Mansoor L
AIDS Care
. 2023 Sep;
36(3):326-342.
PMID: 37734338
Open-Label Extension (OLE) studies are important in the drug development process and are used to further support the licensing applications and regulatory approvals of products. We aimed to understand why...
7.
Zondo N, Sobia P, Sivro A, Ngcapu S, Mansoor L, Mahomed S, et al.
Pharmacogenomics
. 2023 Jul;
24(11):599-613.
PMID: 37503696
We investigated if single-nucleotide polymorphisms (SNPs) in ATP-binding cassette (ABC) drug transporters alter gene expression and tenofovir disposition in South African women taking Truvada for HIV prevention. In 393 women,...
8.
Beesham I, Milford C, Smit J, Davey D, Baeten J, Heffron R, et al.
BMC Public Health
. 2023 Jun;
23(1):1210.
PMID: 37349816
Background: HIV endpoint-driven clinical trials increasingly provide oral pre-exposure prophylaxis (PrEP) as standard of prevention during the trial, however, among participants desiring to continue using PrEP at trial exit, little...
9.
Jansen van Vuuren C, Lewis L, Harkoo I, Dawood H, Mansoor L
AIDS Behav
. 2023 May;
27(11):3596-3602.
PMID: 37221330
New pre-exposure prophylaxis (PrEP) strategies tailored to the needs and expectations of individuals at risk of HIV acquisition are needed. In the CAPRISA 082 prospective cohort study in KwaZulu-Natal, South...
10.
Browne E, Torjesen K, Gati Mirembe B, Palanee-Phillips T, Jeenarain N, Chitukuta M, et al.
AIDS Care
. 2023 Apr;
36(1):80-86.
PMID: 37066990
We assessed if acceptability of the dapivirine vaginal ring for HIV prevention differed among the subgroup of women who reported engaging in transactional sex prior to enrollment in MTN-020/ASPIRE (phase...